Matrix Pharmaceutical (MATX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matrix Pharmaceutical (MATX)

MATX 132.00

+0.7%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JLIHAI who wrote (234)	11/3/1999 1:25:00 PM
From: sydney	of 240

Matrix Reports First Phase II results for Intradose in primary liver cancer at NY cancer meeting...Nov. 3, 1999 (BWHealthwire). 41% with HHC responded to treatment with Intradose Injectable Gel. The results will be presented today at the 17th Annual Chemotherapy Foundation Symposium in NY. It states of 12 responders, 6 have experienced 100% reduction in tumor volume...another 6 or more 50%...10 remain in remission at this date and 2 have remained in remission for 200days. Participating American studies at John Hopkins,Northwestern,St. Vincents, and Louisiana State University Hospital Med Center. Presentation will be made by Dr. Johnson Dept. of Clinical Oncology,Prince of Wales Hospital, the Chinese University of Hong Kong, the leading enrollment study center. In summary: Dr. Johnson says:"Data to data indicate that Intradose is having a significant effect in producing clinical remissions and is showing an encouraging trend toward improved survival." Our prayers go out to Walter Payton's family.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next